NO20040047L - Farmasoytisk formulering for intramuskulaer administrering av fulvestrant - Google Patents

Farmasoytisk formulering for intramuskulaer administrering av fulvestrant

Info

Publication number
NO20040047L
NO20040047L NO20040047A NO20040047A NO20040047L NO 20040047 L NO20040047 L NO 20040047L NO 20040047 A NO20040047 A NO 20040047A NO 20040047 A NO20040047 A NO 20040047A NO 20040047 L NO20040047 L NO 20040047L
Authority
NO
Norway
Prior art keywords
fulvestrant
pharmaceutical formulation
intramuscular administration
intramuscular
administration
Prior art date
Application number
NO20040047A
Other languages
English (en)
Norwegian (no)
Inventor
Julie Kay Cahill
Paul Richard Gellert
Alan Marshall Irving
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20040047L publication Critical patent/NO20040047L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20040047A 2001-07-07 2004-01-06 Farmasoytisk formulering for intramuskulaer administrering av fulvestrant NO20040047L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30
PCT/GB2002/003092 WO2003006064A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Publications (1)

Publication Number Publication Date
NO20040047L true NO20040047L (no) 2004-02-23

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040047A NO20040047L (no) 2001-07-07 2004-01-06 Farmasoytisk formulering for intramuskulaer administrering av fulvestrant

Country Status (15)

Country Link
EP (1) EP1406662A1 (is)
JP (1) JP2004534093A (is)
CN (1) CN1553815A (is)
AR (1) AR037138A1 (is)
BR (1) BR0210898A (is)
CA (1) CA2453111A1 (is)
CO (1) CO5560585A2 (is)
HU (1) HUP0400115A3 (is)
IL (1) IL159576A0 (is)
IS (1) IS7097A (is)
MX (1) MXPA04000028A (is)
NO (1) NO20040047L (is)
PL (1) PL367624A1 (is)
RU (1) RU2004102393A (is)
WO (1) WO2003006064A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US8586092B2 (en) 2009-08-31 2013-11-19 Xi'an Libang Pharmaceutical Technology Co., Ltd. Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
JP6682163B2 (ja) * 2016-04-06 2020-04-15 富士フイルム株式会社 医薬組成物
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
MX2018013414A (es) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos para su uso.
CN109152785B (zh) 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
JP7220712B2 (ja) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
US20220370359A1 (en) * 2019-12-11 2022-11-24 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
IS7097A (is) 2004-01-05
CA2453111A1 (en) 2003-01-23
JP2004534093A (ja) 2004-11-11
MXPA04000028A (es) 2004-05-21
WO2003006064A1 (en) 2003-01-23
CO5560585A2 (es) 2005-09-30
RU2004102393A (ru) 2005-03-27
BR0210898A (pt) 2004-06-22
IL159576A0 (en) 2004-06-01
EP1406662A1 (en) 2004-04-14
HUP0400115A2 (hu) 2004-06-28
AR037138A1 (es) 2004-10-27
CN1553815A (zh) 2004-12-08
HUP0400115A3 (en) 2005-11-28
PL367624A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
NO20033384L (no) Farmasoytisk formulering
NO20033785L (no) Farmasöytisk formulering
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
ITTO20010008A0 (it) Formulazione farmaceutica
NO20033556L (no) Farmasöytiske formuleringer
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
IS6994A (is) Arípíprazóllausn til gjafar um munn
EE05123B1 (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
ITRM20000491A0 (it) Formulazione farmaceutica di propionato di fluticasone.
NO20035627D0 (no) Farmasöytisk formulering
NO20040047L (no) Farmasoytisk formulering for intramuskulaer administrering av fulvestrant
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
EE05020B1 (et) Glburiidi ravimkoostis
IS7051A (is) Lyfjasamsetningar
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
AR025867A1 (es) Formulacion portasdora farmaceutica
DK1385512T3 (da) Anvendelse af pyridoindolonderivater til fremstilling af anticancerlægemidler
GB0201607D0 (en) Formulation for the administration of medicinal substances
NO20041236L (no) Farmasoytisk formulering
SE0102572D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application